Tubulin Targeting Agents

Update on Cancer Therapeutics

Volumn 2, Issue 1, 2007, Pages 1-18

  Hait, William N ^a,b   Rubin, Eric ^a,b   Alli, Elizabeth ^c   Goodin, Susan ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti microtubule drugs; Clinical results; Epothilones; P53; Taxanes; Vinca alkaloids

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIMITOTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DISCODERMOLIDE; DOCETAXEL; DOXORUBICIN; ELEUTHEROBIN; ESTRAMUSTINE; FLUOROURACIL; GEMCITABINE; GLUTAMINE; ISOTRETINOIN; IXABEPILONE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISOLONE; PREDNISONE; TAXANE DERIVATIVE; TRASTUZUMAB; TUBULIN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE; WARFARIN;

ABDOMINAL PAIN; ADD ON THERAPY; ALOPECIA; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASCITES; ASTHENIA; AUTOPHAGY; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; BRONCHOSPASM; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CELL CYCLE; CELL DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLITIS; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COUGHING; DESQUAMATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; ENTEROCOLITIS; EPIPHORA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GRANULOCYTOPENIA; GYNECOMASTIA; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMORRHAGIC GASTRITIS; HUMAN; INDUCED HYPOTENSION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MALAISE; MICROTUBULE; MICROTUBULE ASSEMBLY; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; ONYCHOLYSIS; OVARY CANCER; PAIN; PARESTHESIA; PATIENT SELECTION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; SINUS TACHYCARDIA; SKIN FIBROSIS; SKIN MANIFESTATION; STOMATITIS; TENDON REFLEX; TESTIS CANCER; THORAX PAIN; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 34250783159     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.10.001     Document Type: Review

References (188)

1. Downing K.H., and Nogales E. Tubulin structure: insights into microtubule properties and functions. Curr Opin Struct Biol 8 6 (1998) 785-791
2. Wilson L., and Jordan M.A. Microtubule dynamics: taking aim at a moving target. Chem Biol 2 9 (1995) 569-573
3. Mitchison T., and Kirschner M. Dynamic instability of microtubule growth. Nature 312 5991 (1984) 237-242
4. Olmstead J. Microtubule-associated proteins. Anu Rev Cell Biol 2 (1986) 421
5. Ookata K., et al. Cyclin B interaction with microtubule-associated protein 4 (MAP4) targets p34cdc2 kinase to microtubules and is a potential regulator of M-phase microtubule dynamics. J Cell Biol 128 5 (1995) 849-862
6. Marklund U., et al. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J 15 19 (1996) 5290-5298
7. Curmi P.A., et al. Stathmin and its phosphoprotein family: general properties, biochemical and functional interaction with tubulin. Cell Struct Funct 24 5 (1999) 345-357
8. Belmont L.D., and Mitchison T.J. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84 4 (1996) 623-631
9. Curmi P.A., et al. The stathmin/tubulin interaction in vitro. J Biol Chem 272 40 (1997) 25029-25036
10. Ravelli R.B., et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428 6979 (2004) 198-202
11. Howell B., et al. Dissociation of the tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 18/stathmin. Mol Biol Cell 10 1 (1999) 105-118
12. Ahn J., et al. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18 43 (1999) 5954-5958
13. Murphy M., et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13 19 (1999) 2490-2501
14. Murphy M., Hinman A., and Levine A.J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 10 23 (1996) 2971-2980
15. Dumontet C., and Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17 3 (1999) 1061-1070
16. Hamel E. Antimitotic natural products and their interactions with tubulin. Med Res Rev 16 2 (1996) 207-231
17. Long B.H., et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res 58 6 (1998) 1111-1115
18. Nicolaou K.C., et al. Solid- and solution-phase synthesis of vancomycin and vancomycin analogues with activity against vancomycin-resistant bacteria. Chemistry 7 17 (2001) 3798-3823
19. Leoni L.M., et al. Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J Natl Cancer Inst 92 3 (2000) 217-224
20. Speicher L.A., et al. Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Mol Pharmacol 46 5 (1994) 866-872
21. Tan T.T., et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 7 3 (2005) 227-238
22. Folkman J. Angiogenesis research: from laboratory to clinic. Forum (Genova) 9 3 Suppl. 3 (1999) 59-62
23. Johnson I.S. Historical background of Vinca alkaloid research and areas of future interest. Cancer Chemother Rep 52 4 (1968) 455-461
24. Himes R.H. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51 2 (1991) 257-267
25. Burstein H.J., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 15 (2003) 2889-2895
26. Burstein H.J., et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19 10 (2001) 2722-2730
27. Jahanzeb M., et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 7 5 (2002) 410-417
28. ® againist human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat 1999;57:114.
29. Gridelli C., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 16 (2003) 3025-3034
30. Gridelli C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 5 (2003) 362-372
31. Freyer G., et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21 1 (2003) 35-40
32. Wall M.E., and Wani M.C. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55 4 (1995) 753-760
33. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 5698 (1979) 665-667
34. Ibrahim N.K., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8 5 (2002) 1038-1044
35. Huizing M.T., et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 15 1 (1997) 317-329
36. Blagosklonny M.V., et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56 8 (1996) 1851-1854
37. Klauber N., et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57 1 (1997) 81-86
38. Haldar S., Chintapalli J., and Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56 6 (1996) 1253-1255
39. Strobel T., et al. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res 58 21 (1998) 4776-4781
40. Jones SEJ, Overmoyer B, et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2003; 82(Suppl. 1) [abstract 10].
41. Valero V., et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16 10 (1998) 3362-3368
42. Bear H.D., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 22 (2003) 4165-4174
43. Smith I.C., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20 6 (2002) 1456-1466
44. O'Shaughnessy J., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 12 (2002) 2812-2823
45. Sawada N., et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4 4 (1998) 1013-1019
46. Kurosumi M., et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 7 5 (2000) 945-948
47. Nadella P., et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 20 11 (2002) 2616-2623
48. Jassem J., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19 6 (2001) 1707-1715
49. Nabholtz J.M., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21 6 (2003) 968-975
50. Sledge G.W., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21 4 (2003) 588-592
51. Nabholtz J-M, Paterson A, Dirix L, Dewar J, et al. A phase III randomized trial comparing docetaxel, doxorubicin, and cyclophosphamide to FAC as first line chemotherapy for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2001;20 [abstract 83].
52. Martin M., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 22 (2005) 2302-2313
53. Hinton S., et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20 7 (2002) 1859-1863
54. Dreicer R., et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 97 11 (2003) 2743-2747
55. Vaughn D.J., et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 95 5 (2002) 1022-1027
56. Bajorin D.F., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 10 (1999) 3173-3181
57. Tannock I.F., de Wit R., Berry W.R., Horti J., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced cancer. N Engl J Med 351 (2004) 1502-1512
58. Goodin S., Medina P., Capanna T., Winnie J., Shih J., Abrams S., et al. A phase II trial of docetaxel in patients with D0 prostate cancer. J Clin Oncol 23 15 (2005) 3352-3357
59. Ozols R.F., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 17 (2003) 3194-3200
60. Markman M., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21 13 (2003) 2460-2465
61. Salminen E., et al. Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. J Clin Oncol 17 4 (1999) 1127
62. Seidman AD, Berry D, Cirrincione C, Harris L, et al. CALGB 840: Phase III study of weekly paclitaxel via 1-h infusion versus standard 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004; ASCO Annual Meeting Proceedings, 22 (14S) [Abstract 512].
63. Green M.C., Buzdar A.U., Smith T., Ibrahim N.K., et al. Weekly paclitaxel improved pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23 (2005) 5938-5992
64. Venook A.P., et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16 5 (1998) 1811-1819
65. Bruno R., et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16 1 (1998) 187-196
66. Colombo T., et al. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol 10 4 (1999) 391-395
67. Esposito M., et al. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 17 4 (1999) 1132
68. Gianni L., et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15 5 (1997) 1906-1915
69. Venturini M., et al. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol 18 10 (2000) 2116-2125
70. Chang S.M., et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 16 6 (1998) 2188-2194
71. DiPaola R.S., et al. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol 17 7 (1999) 2213-2218
72. Schrijvers D., et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4 7 (1993) 610-611
73. Esmaeli B., Amin S., Balero V., Adinin R., et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 24 (2006) 3619-3622
74. Kintzel P.E., Michaud L.V., and Lange M. Docetaxel-associated epiphora. Pharmacotherapy 26 (2006) 853-867
75. Markman M., et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18 1 (2000) 102-105
76. Tsavaris N.B., and Kosmas C. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration. Cancer Chemother Pharmacol 42 6 (1998) 509-511
77. Dombernowsky P., et al. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23 5 Suppl 11 (1996) 23-27
78. Gianni L., et al. Paclitaxel by 3-h infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13 11 (1995) 2688-2699
79. Sparano J.A., et al. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol 17 3 (1999) 880-886
80. Savarese D., Boucher J., and Corey B. Glutamine treatment of paclitaxel-induced myalgias and arthralgias. J Clin Oncol 16 12 (1998) 3918-3919
81. Jacobson S.D., et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 1 4 (2003) 274-278
82. Ibrahim N.K., et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355 9200 (2000) 281-283
83. de Matteis A., et al. Intestinal side-effects of docetaxel/vinorelbine combination. Lancet 355 9209 (2000) 1098-1099
84. Stemmler H.J., et al. Gastrointestinal toxicity associated with weekly docetaxel treatment. Ann Oncol 13 6 (2002) 978-981
85. Tew K.D., and Hartley-Asp B. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology 23 6 Suppl (1984) 28-33
86. Stearns M.E., and Tew K.D. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res 45 8 (1985) 3891-3897
87. Weitzman A.L., et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 163 3 (2000) 834-837
88. Oh W.K., et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 98 12 (2003) 2592-2598
89. Vaughn D.J., et al. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. Cancer 100 4 (2004) 746-750
90. Petrylak D.P., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 15 (2004) 1513-1520
91. Hudes G., et al. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J Clin Oncol 20 4 (2002) 1115-1127
92. Kelly W.K., et al. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin Cancer Res 9 6 (2003) 2098-2107
93. Bollag D.M., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55 11 (1995) 2325-2333
94. Kowalski R.J., Giannakakou P., and Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272 4 (1997) 2534-2541
95. Chou T.C., et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci USA 98 14 (2001) 8113-8118
96. Lee F.Y., et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7 5 (2001) 1429-1437
97. Giannakakou P., et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97 6 (2000) 2904-2909
98. Nogales E., et al. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 375 6530 (1995) 424-427
99. Calvert PM, O'Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, inpatients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:429.
100. Rubin EH, Siu LL, Beers S, Moore MJ, Thompson C. A phase I and pharmacologic trial of weekly epothilone B in patients with advanced malignancies. Proc Am Soc Clin Oncol 2001;20:270.
101. Mani S, Mc Daio H, Shen H-J, et al. Phase I evaluation of an epothilone B analog (BMS-247550): clinical findings and molecular correlates. Proc Am Soc Clin Oncol 2001;20:269.
102. Spriggs D, Soignet S, Bienvenu B. Phase I first-in-man study of the epothilone B analog BMS0247550 in patients with advanced cancer. Proc Am Soc Clin Oncol 2001;20:428.
103. Awada A, Bleiberg H, de Valeriola D, et al. Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:427.
104. Ajani JA, Shah MA, Bokemeyer C, Lenz H-J, Burris HI, Van Cutsem E, Usakewicz J, Peeters O, Voi M, Lebwohl D, Safran H. Phase II study of the novel epothilone BMS-247550 in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Proc Am Soc Clin Oncol 2002;21:a619.
105. Roche H., Delord J.P., Bunnell C.A., Perez E.A., Yelle L., Martin M., et al. Phase II studies of the novel epothilone BMS-247550 in patients with taxane-naive or taxane-refractory breast cancer. Proc Am Soc Clin Oncol 21 (2002) p. a223
106. Hood K.A., et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule- stabilizing activity. Cancer Res 62 12 (2002) 3356-3360
107. Kowalski R.J., et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 52 4 (1997) 613-622
108. Martello L.A., et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 6 5 (2000) 1978-1987
109. McDaid H.M., et al. Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines. Cancer Chemother Pharmacol 44 2 (1999) 131-137
110. Karjala G., et al. Ceratamines, structurally simple microtubule-stabilizing antimitotic agents with unusual cellular effects. Cancer Res 65 8 (2005) 3040-3043
111. Bai R.L., Pettit G.R., and Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265 28 (1990) 17141-17149
112. Toppmeyer D.L., et al. Role of P-glycoprotein in dolastatin 10 resistance. Biochem Pharmacol 48 3 (1994) 609-612
113. Madden T., et al. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 6 4 (2000) 1293-1301
114. Pitot H.C., et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5 3 (1999) 525-531
115. Aguayo A, Kraut EH, Moore DF, et al. Phase II study of dolastatin 10 administered intravenously every 21 days to patients with metastatic colorectal cancer. Proc Amer Soc Clin Oncol 2000;19:a1127.
116. Margolin KA, Longmate J, Gandara DR, et al. Dolastatin-10 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Proc Amer Soc Clin Oncol 2000;19:a2243.
117. Vaishampayan U., et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 6 11 (2000) 4205-4208
118. Villalona-Calero M.A., et al. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. J Clin Oncol 16 8 (1998) 2770-2779
119. Supko J.G., et al. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemother Pharmacol 46 4 (2000) 319-328
120. Smyth J., et al. Activity of the dolastatin analogue, LU103793, in malignant melanoma. Ann Oncol 12 4 (2001) 509-511
121. Smith C.D., and Zhang X. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin. J Biol Chem 271 11 (1996) 6192-6198
122. Wagner M.M., et al. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother Pharmacol 43 2 (1999) 115-125
123. Stevenson J.P., et al. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin Cancer Res 8 8 (2002) 2524-2529
124. Menon K., et al. Antitumor activity of cryptophycins: effect of infusion time and combination studies. Cancer Chemother Pharmacol 46 2 (2000) 142-149
125. Hua X.H., et al. Biochemical genetic analysis of indanocine resistance in human leukemia. Cancer Res 61 19 (2001) 7248-7254
126. Towle M.J., et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61 3 (2001) 1013-1021
127. Bai R., et al. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol Pharmacol 44 4 (1993) 757-766
128. Huang Y.T., et al. CIL-102 interacts with microtubule polymerization and causes mitotic arrest following apoptosis in the human prostate cancer PC-3 cell line. J Biol Chem 280 4 (2005) 2771-2779
129. Chen Z., et al. A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth. Mol Cancer Ther 4 4 (2005) 562-568
130. Sengupta S., et al. 4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system. Br J Pharmacol 145 (2005) 1076-1083
131. Bergnes G., Brejc K., and Belmont L. Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem 5 2 (2005) 127-145
132. Marcus A.I., et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem 280 12 (2005) 11569-11577
133. Ueda K., et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 141 3 (1986) 956-962
134. Biedler J.L., et al. Membrane-mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells. J Natl Cancer Inst 55 3 (1975) 671-680
135. Ling V., and Thompson L.H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83 1 (1974) 103-116
136. Moscow J.A., and Cowan K.H. Multidrug resistance. J Natl Cancer Inst 80 1 (1988) 14-20
137. Speicher L.A., et al. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst 86 9 (1994) 688-694
138. Cole S.P., et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 5088 (1992) 1650-1654
139. McGrath T., and Center M.S. Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein. Biochem Biophys Res Commun 145 3 (1987) 1171-1176
140. Keppler D., Jedlitschky G., and Leier I. Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol 292 (1998) 607-616
141. Paul S., et al. Structure and in vitro substrate specificity of the murine multidrug resistance-associated protein. Biochemistry 35 42 (1996) 13647-13655
142. Deeley R.G., and Cole S.P. Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8 3 (1997) 193-204
143. List A.F. Non-P-glycoprotein drug export mechanisms of multidrug resistance. Semin Hematol 34 4 Suppl. 5 (1997) 20-24
144. Cole S.P., et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54 22 (1994) 5902-5910
145. Lorico A., et al. Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res 56 23 (1996) 5351-5355
146. Scotto KW, Egan DA. Transcriptional regulation of MDR genes. Cytotechnology 1998;27:257-69.
147. Chin K.V., et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255 5043 (1992) 459-462
148. Sullivan G.F., et al. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 105 9 (2000) 1261-1267
149. Sullivan G.F., et al. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4 6 (1998) 1393-1403
150. Cornwell M.M., and Smith D.E. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem 268 21 (1993) 15347-15350
151. Cvijic M.E., and Chin K.V. Regulation of P-glycoprotein expression in cyclic AMP-dependent protein kinase mutants. Cell Growth Differ 8 12 (1997) 1243-1247
152. Yao D., et al. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 294 1 (2000) 387-395
153. McFadyen M.C., et al. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 62 2 (2001) 207-212
154. Rao S., et al. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J Biol Chem 270 35 (1995) 20235-20238
155. Rao S., et al. 3′-(p-Azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 269 5 (1994) 3132-3134
156. Rao S., et al. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. J Biol Chem 274 53 (1999) 37990-37994
157. Kavallaris M., et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100 5 (1997) 1282-1293
158. Kavallaris M., Burkhart C.A., and Horwitz S.B. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80 7 (1999) 1020-1025
159. Kamath K., et al. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280 13 (2005) 12902-12907
160. Jaffrezou J.P., et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 7 10-11 (1995) 517-527
161. Cabral F., Abraham I., and Gottesman M.M. Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci USA 78 7 (1981) 4388-4391
162. Ferlini C., et al. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 65 6 (2005) 2397-2405
163. Sirotnak F.M., et al. Markedly decreased binding of vincristine to tubulin in vinca alkaloid-resistant Chinese hamster cells is associated with selective overexpression of alpha and beta tubulin isoforms. Biochem Biophys Res Commun 269 1 (2000) 21-24
164. Yang C.P., et al. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther 4 6 (2005) 987-995
165. Zhang C.C., et al. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 59 15 (1999) 3663-3670
166. Zhang C.C., et al. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16 12 (1998) 1617-1624
167. Alli E., et al. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62 23 (2002) 6864-6869
168. Martello L.A., et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 63 6 (2003) 1207-1213
169. Rouzier R., et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102 23 (2005) 8315-8320
170. Gigant B., et al. Structural basis for the regulation of tubulin by vinblastine. Nature 435 7041 (2005) 519-522
171. Blagosklonny M.V., et al. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 105 4 (2000) 533-539
172. Sumantran V.N., et al. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55 12 (1995) 2507-2510
173. Tang C., et al. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8 11 (1994) 1960-1969
174. Tsujimoto Y., and Croce C.M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83 14 (1986) 5214-5218
175. Hockenbery D., et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 6299 (1990) 334-336
176. Yang J., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 5303 (1997) 1129-1132
177. Yuan J., et al. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 75 4 (1993) 641-652
178. Boulakia C.A., et al. Bcl-2 and adenovirus E1B 19 kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase. Oncogene 12 3 (1996) 529-535
179. Lazebnik Y.A., et al. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371 6495 (1994) 346-347
180. Blagosklonny M.V., et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57 1 (1997) 130-135
181. Haldar S., Jena N., and Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92 10 (1995) 4507-4511
182. Haldar S., Basu A., and Croce C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res 57 2 (1997) 229-233
183. Du L., Lyle C.S., and Chambers T.C. Characterization of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation: evidence for a novel protein kinase and a coordinated phosphorylation/dephosphorylation cycle associated with apoptosis induction. Oncogene 24 1 (2005) 107-117
184. Zhang M., et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 64 3 (2005) 293-302
185. Lowe S.W., et al. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 6 (1993) 957-967
186. Hait W.N., Jin S., and Yang J.M. A matter of life or death (or both): understanding autophagy in cancer. Clin Cancer Res 12 7 Pt 1 (2006) 1961-1965
187. Bash-Babula J., et al. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res 8 5 (2002) 1057-1064
188. Kearney T, R.M., Reidy J, Orlick M, Labassi M, Hait W, Toppmeyer D, DiPaola R. 13-cis Retinoic acid, alpha-interferon and paclitaxel: activity and effect on bcl-2 expression in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2001;20:196.